2024 Antimicrobial Use Option Data Report – January 2026

The 2024 AU Option Data Report summarizes the distributions of SAARs and antimicrobial use across each SAAR agent category for adult, pediatric, and neonatal patient care locations, a detailed in Table 1. The distributions of SAARs allow hospitals and group users to compare their SAARs with the national and state (if sufficient sample size) averages. Hospital antibiotic stewardship teams can use these distributions to establish hospital-specific targets within the NHSN Targeted Assessment for Antimicrobial Stewardship (TAS) Strategy. The percentage of antimicrobial use by class and drug within each SAAR category offers insights into prescribing practices across various types of patient care locations. Hospital stewardship staff can assess usage patterns in relation to local treatment guidelines, penicillin allergy protocols, antimicrobial resistance patterns and rates, and formulary options

[
  {
    "fn": "CDC Info",
    "@type": "Kind",
    "hasEmail": "mailto:cdcinfo@cdc.gov"
  }
]

[
  "Antimicrobial Use and Resistance"
]

{
  "name": "National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of Healthcare Quality Promotion (DHQP)",
  "@type": "Organization",
  "subOrganizationOf": [
    {
      "name": "Centers for Disease Control and Prevention (CDC)",
      "@type": "Organization",
      "subOrganizationOf": [
        {
          "name": "U.S. Department of Health and Human Services",
          "@type": "Organization"
        }
      ]
    }
  ]
}

[
  {
    "@type": "Concept",
    "prefLabel": "Antimicrobial Use"
  }
]